Pharming Group N.V., a biopharmaceutical firm based in Leiden, the Netherlands, has been a key player in developing and marketing protein replacement therapies and precision medicines to tackle rare illnesses in Europe, the United States, and other parts of the world. The company's flagship offering is RUCONEST, a protein replacement therapy free of plasma-based rhC1INH that helps treat acute hereditary angioedema (HAE) attacks. Apart from this, Pharming is also working on other groundbreaking therapies such as leniolisib to counter activated phosphoinositide 3-kinase delta syndrome, OTL-105 - an investigational autologous hematopoietic stem cell gene therapy - to treat HAE, and alpha-glucosidase therapy, aimed at addressing Pompe and fabry diseases. Pharming's strategic alliances and collaborations with Novartis and Orchard Therapeutics plc are expected to drive the company's future growth. Under these agreements, the company will invest in research, development, manufacturing, and commercialization of OTL-105, an innovative ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. In summary, Pharming Group N.V.'s breakthrough therapies, extensive partnerships, and innovative research initiatives have made it a significant player in the biopharmaceutical industry, focused on improving patients' lives by introducing precision medications to treat rare diseases.
Pharos Energy plc's ticker is PHAR
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 51-200 employees working at Pharos Energy plc
It is https://www.pharos.energy/
Pharos Energy plc is in the Energy sector